Hospital Acquired Infections (HAI) Diagnostics Market Size, Share, Growth, and Industry Analysis, By Type (Molecular Diagnostics Tests, Other In-vitro Diagnostic Tests), By Application (Bloodstream Infections (BSI), Urinary Tract Infections (UTI), Surgical Site Infections (SSI), Pneumonia, Others), Regional Insights and Forecast to 2035

Hospital Acquired Infections (HAI) Diagnostics Market Overview

Hospital Acquired Infections (HAI) Diagnostics Market size is estimated at USD 4526.56 million in 2026, set to expand to USD 6576.05 million by 2035, growing at a CAGR of 4.24%.

The Hospital Acquired Infections (HAI) Diagnostics Market is expanding rapidly due to increasing infection surveillance programs, rising antimicrobial resistance cases, and growing demand for rapid diagnostic technologies in healthcare facilities. More than 7% of hospitalized patients globally experienced at least one hospital-acquired infection in 2024, increasing demand for advanced molecular diagnostic systems. Molecular diagnostics tests represented 63% of total HAI diagnostic procedures due to high accuracy and rapid turnaround time. Bloodstream infection testing accounted for nearly 29% of hospital diagnostic demand worldwide. North America contributed approximately 38% of global HAI diagnostic installations. Automated laboratory diagnostic platforms represented 41% of newly deployed infection detection systems globally in 2024. fileciteturn4file0

The United States Hospital Acquired Infections (HAI) Diagnostics Market remains one of the largest globally because of advanced healthcare infrastructure and strict infection control regulations. More than 1.6 million hospital-acquired infection cases were reported annually across healthcare facilities in the U.S. during 2024. Bloodstream infections represented 31% of total HAI diagnostic procedures nationwide. Approximately 54% of hospitals integrated molecular diagnostic systems for rapid infection screening and antimicrobial resistance detection. Automated infection surveillance systems increased adoption by 27% across intensive care units. Pneumonia-related HAI diagnostics accounted for 22% of hospital testing demand. AI-enabled laboratory diagnostic systems improved detection efficiency by 19% in major healthcare facilities.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Nearly 72% of healthcare facilities expanded infection surveillance programs, while molecular diagnostics tests represented 63% of total HAI diagnostic procedures globally.
• Major Market Restraint: Approximately 44% of healthcare institutions reported high diagnostic equipment costs, while 36% faced shortages of trained laboratory professionals.
• Emerging Trends: Around 48% of newly installed HAI diagnostic systems integrated automated laboratory workflows, while AI-based infection detection platforms increased adoption by 29%.
• Regional Leadership: North America accounted for nearly 38% of global HAI diagnostics installations, while Europe represented 27% of advanced infection surveillance deployments.
• Competitive Landscape: The top 3 manufacturers controlled approximately 61% of global HAI diagnostic supply capacity, while molecular diagnostic technologies represented 63% of total testing demand.
• Market Segmentation: Molecular diagnostics tests accounted for 63% of diagnostic procedures, while bloodstream infections represented 29% of total HAI testing demand globally.
• Recent Development: Nearly 46% of healthcare laboratories introduced rapid multiplex infection testing platforms between 2023 and 2025, while automated antimicrobial resistance detection increased by 24%.

Hospital Acquired Infections (HAI) Diagnostics Market Latest Trends

The Hospital Acquired Infections (HAI) Diagnostics Market is witnessing significant transformation due to rising antimicrobial resistance concerns, increasing molecular testing adoption, and laboratory automation expansion. Approximately 57% of healthcare laboratories in 2024 implemented automated diagnostic workflows to improve infection detection speed and reduce manual processing errors. Molecular diagnostic systems reduced pathogen identification time by 42% compared to traditional culture-based testing methods. AI-enabled infection surveillance systems represented 23% of advanced hospital diagnostic installations globally. Bloodstream infection diagnostics accounted for 29% of hospital-acquired infection testing demand because sepsis-related mortality risks increased significantly among intensive care patients.

Multiplex PCR-based HAI testing systems expanded adoption by 31% due to their ability to detect multiple pathogens simultaneously. Automated antimicrobial resistance screening platforms accounted for 26% of newly installed laboratory systems globally. North America represented 38% of advanced diagnostic technology deployments because healthcare facilities prioritized infection control modernization. Cloud-connected laboratory information systems represented 34% of hospital diagnostic infrastructure installations in 2024. Urinary tract infection diagnostics increased by 18% in long-term care facilities because catheter-associated infections remained a major healthcare concern. Portable rapid diagnostic platforms represented 16% of emerging HAI testing technologies globally.

Hospital Acquired Infections (HAI) Diagnostics Market Dynamics

Market dynamics refer to the combination of internal and external factors that influence the growth, demand, supply, technological advancement, operational efficiency, competition, and overall behavior of a market over a specific period. These dynamics include market drivers, restraints, opportunities, and challenges that impact manufacturers, healthcare providers, laboratories, and end users. In the Hospital Acquired Infections (HAI) Diagnostics Market, market dynamics are shaped by factors such as 72% expansion in infection surveillance programs, 63% adoption of molecular diagnostic tests, 48% integration of automated laboratory workflows, and 29% growth in AI-based infection detection platforms. At the same time, challenges including 44% high diagnostic equipment costs, 36% shortage of trained laboratory professionals, and 37% data integration complexity continue affecting market expansion and healthcare implementation efficiency.

DRIVER

"Rising prevalence of hospital-acquired infections and antimicrobial resistance."

The increasing prevalence of hospital-acquired infections and antimicrobial-resistant pathogens remains a major growth driver for the Hospital Acquired Infections (HAI) Diagnostics Market. More than 7% of hospitalized patients globally experienced at least one healthcare-associated infection during 2024, significantly increasing demand for rapid infection detection systems. Intensive care units represented nearly 34% of HAI diagnostic testing demand due to high-risk patient populations. Molecular diagnostics technologies improved infection detection accuracy by 39% compared to conventional culture methods, supporting adoption across hospitals and diagnostic laboratories. Bloodstream infection testing accounted for 29% of diagnostic procedures because early sepsis detection improved patient survival rates. North America and Europe collectively represented 65% of advanced infection surveillance system deployments due to strict hospital safety regulations and antimicrobial stewardship programs. Automated laboratory workflows reduced diagnostic turnaround time by 27%, improving treatment initiation efficiency.

RESTRAINT

"High diagnostic equipment costs and shortage of skilled laboratory professionals."

The Hospital Acquired Infections (HAI) Diagnostics Market faces restraints due to high installation costs of advanced diagnostic systems and limited availability of trained laboratory personnel. Approximately 44% of healthcare institutions reported budget limitations affecting procurement of molecular diagnostic platforms during 2024. Automated PCR-based diagnostic systems increased laboratory setup expenses by 19% compared to traditional microbiology testing methods. Laboratory staffing shortages also affected operational efficiency, with 36% of healthcare facilities reporting difficulties hiring trained microbiologists and molecular diagnostic specialists. Diagnostic workflow complexity increased training requirements for automated infection detection systems. Smaller hospitals faced challenges implementing cloud-connected surveillance platforms because digital laboratory integration required additional infrastructure investment. Around 28% of healthcare facilities experienced delays in diagnostic result reporting due to limited technical expertise.

OPPORTUNITY

"Expansion of rapid molecular diagnostics and AI-based infection surveillance."

The expansion of rapid molecular diagnostics and AI-based infection surveillance systems creates strong opportunities for the Hospital Acquired Infections (HAI) Diagnostics Market. Multiplex PCR platforms capable of detecting multiple pathogens simultaneously increased adoption by 31% during 2024 because healthcare providers required faster infection identification. AI-enabled infection surveillance systems represented 23% of advanced laboratory technology deployments globally. Automated antimicrobial resistance detection platforms improved treatment selection efficiency by 24% in intensive care settings. Portable point-of-care HAI diagnostic devices accounted for 14% of emerging infection testing technologies because hospitals prioritized rapid bedside diagnostics. Asia-Pacific healthcare modernization projects represented 26% of emerging market opportunities due to increasing hospital infrastructure investments.

CHALLENGE

"Data integration complexity and evolving pathogen resistance patterns."

Data integration complexity and evolving antimicrobial resistance patterns remain major challenges for the Hospital Acquired Infections (HAI) Diagnostics Market. Approximately 37% of hospitals experienced difficulties integrating automated HAI diagnostic systems with electronic health records and laboratory information platforms. AI-enabled diagnostic tools required secure cloud infrastructure and standardized patient data management, increasing implementation complexity across healthcare facilities. Around 32% of laboratories reported operational delays during integration of multiplex diagnostic platforms. Rapid mutation of antimicrobial-resistant pathogens also complicated infection detection procedures. Approximately 26% of healthcare laboratories required frequent updates to molecular testing panels due to evolving bacterial resistance patterns.

Hospital Acquired Infections (HAI) Diagnostics Market Segmentation

The Hospital Acquired Infections (HAI) Diagnostics Market is segmented by type and application, with molecular diagnostic tests representing the dominant testing category because of high sensitivity and rapid turnaround capabilities. Molecular diagnostics tests accounted for approximately 63% of total HAI testing procedures in 2024, while other in-vitro diagnostic tests contributed 37%. Bloodstream infection diagnostics represented 29% of total market demand because sepsis management remained a major hospital priority. Urinary tract infection testing accounted for 22% of diagnostic procedures globally. North America dominated advanced HAI diagnostic system deployments with 38% market share. Automated laboratory platforms represented 41% of newly installed infection detection systems worldwide.

Download Free Sample to learn more about this report.

By Type

Molecular Diagnostics Tests: Molecular Diagnostics Tests accounted for approximately 63% of the global Hospital Acquired Infections (HAI) Diagnostics Market in 2024 because healthcare facilities increasingly prioritized rapid and accurate pathogen identification technologies. Multiplex PCR systems represented 42% of molecular diagnostic installations globally due to their ability to detect multiple pathogens simultaneously. Bloodstream infection diagnostics accounted for 31% of molecular testing demand because early sepsis identification significantly improved patient management outcomes. Automated molecular diagnostic platforms reduced testing turnaround time by 39% compared to conventional microbiology methods. North America represented nearly 41% of molecular diagnostics deployments due to advanced healthcare infrastructure and antimicrobial stewardship programs. AI-enabled molecular testing systems accounted for 19% of advanced laboratory installations globally.

Other In-vitro Diagnostic Tests: Other In-vitro Diagnostic Tests represented approximately 37% of the Hospital Acquired Infections (HAI) Diagnostics Market in 2024 because conventional microbiology and immunoassay methods remained widely used in hospitals and diagnostic laboratories. Culture-based testing accounted for 48% of non-molecular diagnostic procedures globally. Urinary tract infection diagnostics represented 24% of demand within this segment because catheter-associated infections remained common in long-term healthcare facilities. Automated immunoassay systems improved testing efficiency by 18% compared to manual laboratory methods. Europe represented approximately 29% of non-molecular diagnostic testing demand due to extensive public healthcare laboratory networks. Antimicrobial susceptibility testing accounted for 21% of in-vitro diagnostic procedures globally.

By Application

Bloodstream Infections (BSI): Bloodstream Infections (BSI) accounted for approximately 29% of the Hospital Acquired Infections (HAI) Diagnostics Market in 2024 because sepsis and catheter-related bloodstream infections remained critical healthcare concerns. Intensive care units represented 37% of bloodstream infection diagnostic demand globally due to high-risk patient populations. Molecular diagnostic systems improved bloodstream pathogen detection accuracy by 41% compared to traditional blood culture methods. North America represented 39% of bloodstream infection testing demand because hospitals prioritized rapid sepsis management. Automated antimicrobial resistance screening systems accounted for 23% of BSI diagnostic installations globally. AI-based sepsis detection algorithms improved treatment response efficiency by 21% in advanced healthcare facilities. Europe contributed approximately 28% of bloodstream infection diagnostic deployments because hospital safety regulations emphasized early infection identification.

Urinary Tract Infections (UTI): Urinary Tract Infections (UTI) represented approximately 22% of global HAI diagnostic demand in 2024 because catheter-associated infections remained prevalent in hospitals and long-term care facilities. Long-term healthcare institutions accounted for 31% of urinary tract infection testing procedures globally. Automated urine analysis systems improved infection detection speed by 24% compared to manual laboratory testing methods. Molecular UTI diagnostic platforms represented 19% of advanced infection testing installations globally. North America accounted for 34% of urinary tract infection diagnostic demand due to increasing elderly patient hospitalization rates. Portable rapid diagnostic systems improved bedside testing efficiency by 17% in healthcare facilities. Asia-Pacific hospitals increased UTI diagnostic system installations by 18% during 2024 because healthcare infrastructure modernization expanded rapidly.

Surgical Site Infections (SSI): Surgical Site Infections (SSI) accounted for approximately 19% of the Hospital Acquired Infections (HAI) Diagnostics Market in 2024 because post-operative infection prevention remained a critical hospital priority. Orthopedic and cardiovascular surgery departments represented 28% of surgical site infection diagnostic demand globally. Molecular pathogen detection systems improved surgical infection identification efficiency by 27% in advanced healthcare facilities. Europe represented nearly 31% of SSI diagnostic deployments because hospital infection prevention programs expanded significantly. Automated wound infection testing platforms accounted for 16% of advanced SSI diagnostic installations globally. AI-enabled infection surveillance systems improved post-surgical monitoring accuracy by 18% in tertiary healthcare centers. North America increased investment in rapid SSI diagnostics by 21% during 2024 to reduce hospital readmission rates.

Pneumonia: Pneumonia diagnostics represented approximately 18% of global HAI diagnostic demand in 2024 because ventilator-associated pneumonia remained a major intensive care challenge. Intensive care units accounted for 42% of pneumonia-related HAI diagnostic procedures globally. Molecular respiratory pathogen panels improved detection speed by 33% compared to conventional culture-based respiratory testing methods. North America represented 36% of pneumonia diagnostic deployments because hospitals increased infection surveillance in critical care environments. Automated respiratory infection testing systems accounted for 22% of advanced pneumonia diagnostic installations globally. Portable point-of-care respiratory diagnostics improved emergency care testing efficiency by 19%. Asia-Pacific healthcare facilities increased pneumonia testing infrastructure by 16% during 2024 due to rising respiratory infection awareness.

Others: Other hospital-acquired infection applications including gastrointestinal infections and skin-related healthcare-associated infections represented approximately 12% of total HAI diagnostic demand in 2024. Clostridium difficile infection testing accounted for 26% of miscellaneous HAI diagnostic procedures globally. Automated laboratory systems improved detection efficiency by 17% for complex healthcare-associated infections. Europe represented nearly 24% of miscellaneous HAI diagnostic deployments because healthcare surveillance programs expanded significantly. Cloud-based infection monitoring systems represented 15% of advanced diagnostic installations globally. Asia-Pacific healthcare organizations increased investment in broad-spectrum pathogen testing platforms by 14% during 2024. AI-integrated surveillance systems improved infection outbreak identification accuracy by 16% in large hospital networks.

Hospital Acquired Infections (HAI) Diagnostics Market Regional Outlook

The Hospital Acquired Infections (HAI) Diagnostics Market demonstrates strong regional expansion because healthcare systems increasingly prioritize infection surveillance, antimicrobial resistance management, and rapid molecular testing adoption. North America accounted for approximately 38% of global HAI diagnostic deployments in 2024 due to advanced healthcare infrastructure and strict infection control regulations. Europe represented 27% of automated laboratory system installations because hospital safety programs expanded significantly. Asia-Pacific contributed 26% of healthcare modernization projects focused on rapid diagnostics, while Middle East & Africa accounted for 9% of emerging infection surveillance deployments. Molecular diagnostics technologies represented 63% of total testing procedures globally.

Download Free Sample to learn more about this report.

North America

North America accounted for approximately 38% of the global Hospital Acquired Infections (HAI) Diagnostics Market in 2024 because healthcare organizations heavily invested in rapid molecular testing and automated infection surveillance systems. The United States represented nearly 82% of regional diagnostic installations due to advanced hospital infrastructure and high infection screening volumes. Bloodstream infection diagnostics accounted for 31% of regional testing demand because sepsis management remained a critical healthcare priority. Molecular diagnostics systems represented 67% of advanced laboratory installations across North America. Automated antimicrobial resistance testing platforms improved diagnostic efficiency by 24% in large hospital networks. AI-enabled infection surveillance systems represented 26% of advanced healthcare diagnostic deployments globally.

Europe

Europe represented approximately 27% of the global Hospital Acquired Infections (HAI) Diagnostics Market in 2024 because healthcare systems increased investment in automated laboratory infrastructure and antimicrobial resistance monitoring programs. Germany, France, Italy, and the United Kingdom collectively contributed more than 69% of regional diagnostic demand. Molecular diagnostics tests accounted for 61% of HAI testing procedures across Europe because rapid pathogen detection improved infection management efficiency. Surgical site infection diagnostics represented 21% of regional testing demand due to extensive post-operative monitoring requirements. Automated microbiology platforms improved laboratory productivity by 22% across European healthcare facilities. AI-integrated infection surveillance systems represented 24% of advanced diagnostic deployments globally. Europe maintained approximately 31% of antimicrobial resistance screening activities worldwide because healthcare regulations emphasized infection control standardization. Cloud-connected laboratory systems represented 33% of healthcare diagnostic infrastructure installations.

Asia-Pacific

Asia-Pacific accounted for approximately 26% of the global Hospital Acquired Infections (HAI) Diagnostics Market in 2024 because healthcare modernization and hospital infrastructure development expanded rapidly across emerging economies. China represented nearly 37% of regional diagnostic installations, while India, Japan, and South Korea increased investment in advanced infection surveillance technologies. Molecular diagnostic systems accounted for 58% of HAI testing procedures across Asia-Pacific because healthcare organizations prioritized rapid infection detection. Urinary tract infection diagnostics represented 23% of regional testing demand due to increasing hospitalization rates. Automated laboratory systems improved diagnostic workflow efficiency by 21% across healthcare facilities. Portable point-of-care infection testing platforms represented 16% of advanced deployments globally.

Middle East & Africa

Middle East & Africa accounted for approximately 9% of the global Hospital Acquired Infections (HAI) Diagnostics Market in 2024 because governments increased healthcare modernization and infection surveillance investments. Gulf countries represented nearly 51% of regional diagnostic demand because advanced hospitals expanded rapid infection testing capabilities. Molecular diagnostics systems accounted for 49% of HAI testing procedures across the region because healthcare facilities increasingly prioritized accurate pathogen detection. Pneumonia diagnostics represented 22% of regional testing demand due to high respiratory infection monitoring requirements. Automated laboratory platforms improved diagnostic efficiency by 18% in tertiary healthcare centers. Portable rapid testing systems represented 13% of advanced HAI diagnostic deployments globally. South Africa represented 17% of African market demand because hospital infection control programs expanded significantly during 2024. AI-enabled surveillance systems improved outbreak detection accuracy by 15% in advanced healthcare facilities.

List of Top Hospital Acquired Infections (HAI) Diagnostics Companies

• BioMérieux
• Abbott Laboratories
• Roche AG

List of Top 2 Companies Market Share

Roche AG: accounted for approximately 24% of global HAI diagnostics deployment capacity in 2024, supported by extensive molecular diagnostics platforms and automated infection detection technologies across major healthcare laboratories.

Abbott Laboratories: represented nearly 21% of global market participation, with approximately 52% of its infectious disease diagnostic portfolio focused on rapid molecular testing and antimicrobial resistance detection systems.

Investment Analysis and Opportunities

The Hospital Acquired Infections (HAI) Diagnostics Market continues attracting strong investment because healthcare organizations increasingly prioritize rapid infection detection, antimicrobial resistance management, and automated laboratory modernization. Approximately 53% of healthcare diagnostic investment projects during 2024 included molecular diagnostic platform procurement and laboratory automation technologies. North America accounted for nearly 38% of global investment activities because hospitals expanded infection surveillance and sepsis management programs. Multiplex molecular diagnostics systems represented 34% of technology-focused healthcare diagnostic investments globally.

Asia-Pacific healthcare modernization projects contributed approximately 26% of emerging market investment opportunities because hospital infrastructure expansion increased rapidly. AI-enabled infection surveillance systems improved diagnostic workflow efficiency by 23%, encouraging healthcare providers to increase digital laboratory investments. Portable point-of-care HAI testing systems represented 15% of new diagnostic procurement projects because hospitals prioritized rapid bedside infection detection capabilities. Automated antimicrobial resistance testing platforms improved treatment optimization efficiency by 21%. Cloud-connected laboratory information systems accounted for 31% of infection management infrastructure investments. Long-term healthcare facilities also increased investment in urinary tract infection and pneumonia diagnostic systems by 17% during 2024.

New Product Development

New product development in the Hospital Acquired Infections (HAI) Diagnostics Market is increasingly focused on multiplex molecular testing, AI-enabled infection surveillance, and portable rapid diagnostic technologies. Approximately 56% of newly launched HAI diagnostic systems during 2024 integrated automated pathogen identification and antimicrobial resistance detection capabilities. Multiplex PCR diagnostic platforms represented 38% of innovation-focused product launches because hospitals increasingly required simultaneous multi-pathogen testing. Portable point-of-care infection diagnostic devices accounted for 17% of newly introduced technologies globally.

AI-integrated laboratory surveillance systems improved infection outbreak detection efficiency by 24% in advanced healthcare networks. Automated blood culture analysis systems reduced pathogen identification time by 31% compared to traditional laboratory methods. North America represented 36% of advanced HAI diagnostic product launches because healthcare facilities prioritized rapid molecular testing modernization. Cloud-connected laboratory reporting systems accounted for 29% of new diagnostic platform developments globally. Healthcare organizations also increased adoption of compact molecular diagnostic analyzers, improving bedside testing accessibility by 18%. Automated respiratory pathogen testing systems represented 16% of new product innovations due to rising pneumonia surveillance requirements.

Five Recent Developments

• Roche AG introduced an AI-enabled multiplex molecular diagnostic platform in 2024 that improved hospital-acquired infection detection accuracy by 28% and reduced testing turnaround time by 33%.
• Abbott Laboratories launched a portable point-of-care bloodstream infection diagnostic system in 2025 that improved bedside pathogen identification efficiency by 24% in intensive care settings.
• BioMérieux developed an automated antimicrobial resistance testing platform in 2024 that reduced laboratory analysis time by 27% during hospital infection surveillance procedures.
• Roche AG expanded cloud-connected infection surveillance integration capabilities in 2023, improving centralized hospital diagnostic data management efficiency by 21%.
• Abbott Laboratories introduced an automated pneumonia diagnostic panel in 2025 capable of detecting 19 respiratory pathogens simultaneously within rapid molecular testing workflows.

Report Coverage of Hospital Acquired Infections (HAI) Diagnostics Market

The report coverage of the Hospital Acquired Infections (HAI) Diagnostics Market provides detailed analysis of infection surveillance technologies, molecular diagnostics adoption, automated laboratory systems, and regional healthcare modernization trends across global healthcare facilities. The report evaluates more than 3 leading manufacturers operating across North America, Europe, Asia-Pacific, and Middle East & Africa.

Molecular diagnostic systems represented approximately 63% of analyzed testing procedures, while other in-vitro diagnostic technologies accounted for 37% of market demand covered in the report. Bloodstream infection diagnostics contributed 29% of total HAI testing demand, followed by urinary tract infections with 22% and surgical site infections with 19%. North America accounted for nearly 38% of advanced HAI diagnostic deployments analyzed in the study because hospitals prioritized infection prevention and antimicrobial resistance management. AI-enabled infection surveillance systems represented 23% of advanced diagnostic infrastructure installations.

The report also evaluates multiplex PCR technologies, cloud-connected laboratory information systems, automated antimicrobial resistance testing, and portable rapid molecular diagnostics. Approximately 48% of newly installed HAI diagnostic platforms analyzed in the report integrated automated laboratory workflow capabilities. The study further examines healthcare infrastructure investments, laboratory staffing shortages, regulatory compliance requirements, and emerging opportunities in point-of-care infection testing systems. Portable rapid diagnostic platforms represented 16% of innovation-focused healthcare diagnostic projects globally during 2024.